FATE THERAPEUTICS: Diferență între versiuni
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei FATE THERAPEUTICS listata cu simbolul US.FATE ==Descriere companie== Fate Therapeutics, Inc. (http://fatetherapeutics.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development of programmed cellular immunotherapies for patients with cancer, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master engineered induced pluripotent stem cell (iPSC) lines. Its patent protecte...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 2: | Linia 2: | ||
==Descriere companie== | ==Descriere companie== | ||
Fate Therapeutics, Inc. (http://fatetherapeutics.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development of programmed cellular immunotherapies for patients with cancer, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master engineered induced pluripotent stem cell (iPSC) lines. Its patent protected iPSC platform enables to genetically engineer, single-cell isolate and select iPSCs for clonal expansion as master iPSC lines. Master iPSC lines are an ideal source for creating cell therapy product candidates. The Company's product pipeline includes FT500, FT516, FT538, FT596, FT576, FT819, FT536 and FT573 | Fate Therapeutics, Inc. (http://fatetherapeutics.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development of programmed cellular immunotherapies for patients with cancer, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master engineered induced pluripotent stem cell (iPSC) lines. Its patent protected iPSC platform enables to genetically engineer, single-cell isolate and [[SELECT|select]] iPSCs for clonal expansion as master iPSC lines. Master iPSC lines are an [[IDEAL|ideal]] source for creating cell therapy product candidates. The Company's product pipeline includes FT500, FT516, FT538, FT596, FT576, FT819, FT536 and FT573 | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||
Versiunea curentă din 30 septembrie 2024 20:25
Pagina dedicata companiei FATE THERAPEUTICS listata cu simbolul US.FATE
Descriere companie[edit | ]
Fate Therapeutics, Inc. (http://fatetherapeutics.com/) is a clinical-stage biopharmaceutical company. The Company is focused on the development of programmed cellular immunotherapies for patients with cancer, including off-the-shelf natural killer (NK) and T-cell product candidates derived from clonal master engineered induced pluripotent stem cell (iPSC) lines. Its patent protected iPSC platform enables to genetically engineer, single-cell isolate and select iPSCs for clonal expansion as master iPSC lines. Master iPSC lines are an ideal source for creating cell therapy product candidates. The Company's product pipeline includes FT500, FT516, FT538, FT596, FT576, FT819, FT536 and FT573
Grafic actiuni companie[edit | ]